Author: Yang, Qinzhi; Lin, Fang; Wang, Yanan; Zeng, Min; Luo, Mao
Title: Long Noncoding RNAs as Emerging Regulators of COVID-19 Cord-id: d6vx7o69 Document date: 2021_8_2
ID: d6vx7o69
Snippet: Coronavirus disease 2019 (COVID-19), which has high incidence rates with rapid rate of transmission, is a pandemic that spread across the world, resulting in more than 3,000,000 deaths globally. Currently, several drugs have been used for the clinical treatment of COVID-19, such as antivirals (radecivir, baritinib), monoclonal antibodies (tocilizumab), and glucocorticoids (dexamethasone). Accumulating evidence indicates that long noncoding RNAs (lncRNAs) are essential regulators of virus infecti
Document: Coronavirus disease 2019 (COVID-19), which has high incidence rates with rapid rate of transmission, is a pandemic that spread across the world, resulting in more than 3,000,000 deaths globally. Currently, several drugs have been used for the clinical treatment of COVID-19, such as antivirals (radecivir, baritinib), monoclonal antibodies (tocilizumab), and glucocorticoids (dexamethasone). Accumulating evidence indicates that long noncoding RNAs (lncRNAs) are essential regulators of virus infections and antiviral immune responses including biological processes that are involved in the regulation of COVID-19 and subsequent disease states. Upon viral infections, cellular lncRNAs directly regulate viral genes and influence viral replication and pathology through virus-mediated changes in the host transcriptome. Additionally, several host lncRNAs could help the occurrence of viral immune escape by inhibiting type I interferons (IFN-1), while others could up-regulate IFN-1 production to play an antiviral role. Consequently, understanding the expression and function of lncRNAs during severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection will provide insights into the development of lncRNA-based methods. In this review, we summarized the current findings of lncRNAs in the regulation of the strong inflammatory response, immune dysfunction and thrombosis induced by SARS-CoV-2 infection, discussed the underlying mechanisms, and highlighted the therapeutic challenges of COVID-19 treatment and its future research directions.
Search related documents:
Co phrase search for related documents- abnormal expression and acute ards respiratory distress syndrome: 1
- abnormal expression and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
- acid aptamer and acute sars cov respiratory syndrome coronavirus: 1
- acid induce and activity expression: 1
- acid induce and acute sars cov respiratory syndrome coronavirus: 1
- activate immune cell and acute sars cov respiratory syndrome coronavirus: 1
- activate immune cell and adaptive innate: 1, 2, 3
- activity expression and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- activity expression and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activity expression and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- activity expression and adaptive innate immune response: 1, 2
- acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and administer dose: 1
- acute sars cov respiratory syndrome coronavirus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars cov respiratory syndrome coronavirus and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars cov respiratory syndrome coronavirus and administer dose: 1
Co phrase search for related documents, hyperlinks ordered by date